Department of Neurology, Dysautonomia Center, New York University School of Medicine, New York, New York, USA.
Mov Disord. 2018 Mar;33(3):372-390. doi: 10.1002/mds.27344.
Dysfunction of the autonomic nervous system afflicts most patients with Parkinson disease and other synucleinopathies such as dementia with Lewy bodies, multiple system atrophy, and pure autonomic failure, reducing quality of life and increasing mortality. For example, gastrointestinal dysfunction can lead to impaired drug pharmacodynamics causing a worsening in motor symptoms, and neurogenic orthostatic hypotension can cause syncope, falls, and fractures. When recognized, autonomic problems can be treated, sometimes successfully. Discontinuation of potentially causative/aggravating drugs, patient education, and nonpharmacological approaches are useful and should be tried first. Pathophysiology-based pharmacological treatments that have shown efficacy in controlled trials of patients with synucleinopathies have been approved in many countries and are key to an effective management. Here, we review the treatment of autonomic dysfunction in patients with Parkinson disease and other synucleinopathies, summarize the nonpharmacological and current pharmacological therapeutic strategies including recently approved drugs, and provide practical advice and management algorithms for clinicians, with focus on neurogenic orthostatic hypotension, supine hypertension, dysphagia, sialorrhea, gastroparesis, constipation, neurogenic overactive bladder, underactive bladder, and sexual dysfunction. © 2018 International Parkinson and Movement Disorder Society.
自主神经系统功能障碍影响大多数帕金森病患者和其他突触核蛋白病患者,如路易体痴呆、多系统萎缩和单纯自主神经衰竭,降低生活质量并增加死亡率。例如,胃肠道功能障碍可导致药物药效学受损,从而导致运动症状恶化,神经源性直立性低血压可导致晕厥、跌倒和骨折。当识别出自主问题时,可以进行治疗,有时可以成功治疗。停用可能导致/加重疾病的药物、患者教育和非药物方法是有用的,应首先尝试。已在突触核蛋白病患者的对照试验中显示出疗效的基于病理生理学的药物治疗已在许多国家获得批准,是有效管理的关键。在这里,我们回顾了帕金森病和其他突触核蛋白病患者自主神经功能障碍的治疗方法,总结了非药物和目前的药物治疗策略,包括最近批准的药物,并为临床医生提供了实用的建议和管理算法,重点介绍了神经源性直立性低血压、仰卧位高血压、吞咽困难、流涎、胃轻瘫、便秘、神经源性过度活动膀胱、膀胱活动低下和性功能障碍。 © 2018 国际帕金森病和运动障碍学会。